
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
IDENTIFIER (ClinicalTrials.gov):Â NCT05142696
DRUG/TREATMENT: LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab
PHASE: 1b / 2
STATUS: Recruiting
SPONSOR: Novartis Pharmaceuticals
DESCRIPTION:
Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC." Recorded: June 20, 2024
This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
CONTACT:
Novartis Pharmaceuticals
EMAIL: novartis.email@novartis.com
PHONE:Â 1-888-669-6682
RELATED RESOURCES:
Clinical Trials Using Lutetium Lu 177 Dotatate - NCI
"High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD